Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckBarbara Burtness, Tomoya Yokota, Luciano de Souza Viana et al.|JAMA Oncology|2019Cited by 43
LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).Barbara Burtness, Robert I. Haddad, José Dinis et al.|Journal of Clinical Oncology|2017Cited by 13
Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer.Saranya Chumsri, Carmen Calfa, Chaitali Nangia et al.|Journal of Clinical Oncology|2025Cited by 1